Deutsche Bank AG Makes New Investment in TransMedics Group, Inc. $TMDX

Key Points

• Deutsche Bank initiated a position in TransMedics Group by purchasing 217,031 shares worth approximately $14.4 million, while institutional investors collectively owned 99.67% of the stock.
• TransMedics reported quarterly revenue of $189.95 million, beating estimates and rising 20.7% year over year, but its $0.44 EPS missed the $0.50 consensus estimate.
• Analyst sentiment is mixed: the stock has a consensus “Hold” rating and an average price target of $124.18, while several firms recently downgraded their outlooks despite buy ratings from Canaccord Genuity and TD Cowen.

Deutsche Bank AG purchased a new position in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) in the second quarter, according to its most recent disclosure with the SEC. The firm purchased 217,031 shares of the company's stock, valued at approximately $14,415,000. Deutsche Bank AG owned approximately 0.63% of TransMedics Group at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in TMDX. Persistent Asset Partners Ltd bought a new stake in shares of TransMedics Group in the 2nd quarter valued at approximately $55,000. OneDigital Investment Advisors LLC acquired a new position in TransMedics Group in the second quarter worth approximately $400,000. Flputnam Investment Management Co. bought a new position in TransMedics Group during the second quarter valued at approximately $77,000. Global Retirement Partners LLC bought a new position in TransMedics Group during the second quarter valued at approximately $450,000. Finally, Bank of New York Mellon Corp acquired a new stake in TransMedics Group in the second quarter valued at approximately $12,869,000. 99.67% of the stock is owned by hedge funds and other institutional investors.

TransMedics Group Stock Up 4.3%

Shares of TMDX stock opened at $94.77 on Friday. The stock's 50 day simple moving average is $77.49 and its 200 day simple moving average is $95.32. The company has a debt-to-equity ratio of 1.62, a quick ratio of 6.07 and a current ratio of 6.62. TransMedics Group, Inc. has a twelve month low of $60.10 and a twelve month high of $156.00. The company has a market capitalization of $3.28 billion, a price-to-earnings ratio of 24.36 and a beta of 1.90.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported $0.44 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.50 by ($0.06). TransMedics Group had a return on equity of 15.88% and a net margin of 22.69%.The company had revenue of $189.95 million for the quarter, compared to the consensus estimate of $184.00 million. During the same period in the previous year, the company earned $0.92 EPS. The firm's revenue for the quarter was up 20.7% compared to the same quarter last year. As a group, research analysts predict that TransMedics Group, Inc. will post 1.47 EPS for the current year.

Insider Activity at TransMedics Group

In other news, Director Thomas J. Gunderson sold 9,624 shares of the business's stock in a transaction on Monday, June 15th. The shares were sold at an average price of $75.06, for a total value of $722,377.44. Following the completion of the sale, the director directly owned 16,642 shares in the company, valued at approximately $1,249,148.52. The trade was a 36.64% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 6.90% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several analysts have commented on the stock. Wall Street Zen downgraded shares of TransMedics Group from a "hold" rating to a "sell" rating in a research report on Saturday, May 9th. Canaccord Genuity Group restated a "buy" rating and set a $124.00 price target on shares of TransMedics Group in a report on Tuesday, June 30th. TD Cowen restated a "buy" rating and set a $120.00 price target on shares of TransMedics Group in a report on Wednesday, July 1st. Oppenheimer lowered shares of TransMedics Group from an "outperform" rating to a "market perform" rating in a research note on Wednesday, May 6th. Finally, Zacks Research cut shares of TransMedics Group from a "hold" rating to a "strong sell" rating in a report on Monday, July 6th. Six research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, TransMedics Group presently has a consensus rating of "Hold" and an average price target of $124.18.

TransMedics Group Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company's flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics' solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.

Want to see what other hedge funds are holding TMDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TransMedics Group, Inc. (NASDAQ:TMDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source